Detalles de la búsqueda
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37674077
2.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10411): 1423-1433, 2023 10 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37633306
3.
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Breast Cancer Res Treat
; 2024 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38703285
4.
miR-203 drives breast cancer cell differentiation.
Breast Cancer Res
; 25(1): 91, 2023 08 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37542268
5.
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 380(20): 1929-1940, 2019 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-31091374
6.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
; 22(4): 489-498, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794206
7.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863451
8.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 189(3): 689-699, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34414532
9.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(4): 519-530, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32171426
10.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33152285
11.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838010
12.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33138866
13.
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
Breast Cancer Res Treat
; 184(2): 469-479, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32876911
14.
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
Breast Cancer Res Treat
; 184(2): 421-431, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32770287
15.
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Future Oncol
; 16(33): 2763-2778, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32781837
16.
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Eur J Cancer Care (Engl)
; 29(4): e13253, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32578279
17.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 20(9): 1226-1238, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31402321
18.
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Breast Cancer Res
; 21(1): 108, 2019 09 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31533777
19.
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Oncologist
; 24(7): 893-900, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30679318
20.
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Oncologist
; 24(11): e1024-e1033, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31023863